Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지
DOI QR코드

DOI QR Code

Oocyte cryopreservation for women with endometriosis: Justification, indications, and reproductive outcomes

  • Seung Joo Chon (Department of Obstetrics and Gynecology, Gachon University Gil Medical Center, Gachon University College of Medicine) ;
  • Byung Chul Jee (Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seoul National University College of Medicine)
  • Received : 2023.09.04
  • Accepted : 2024.03.12
  • Published : 2024.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Women with endometriosis often experience diminished ovarian reserve and a decreased number of oocytes retrieved. This reduction is exacerbated after surgery. Nevertheless, oocyte quality does not seem to be compromised in these patients. When embryos of good quality are obtained, in vitro fertilization outcomes are generally satisfactory. Oocyte cryopreservation may represent a fertility preservation option for women with planned and/or prior surgery, as it enables the collection of oocytes in advance. Given the diverse manifestations of endometriosis, which vary by type, age, and ovarian reserve, the decision to pursue oocyte cryopreservation should be weighed individually. Moreover, the potential benefits of this approach on future fertility must be carefully considered. Considering current guidelines, the most appropriate candidates for oocyte cryopreservation among women with endometriosis are: patients with bilateral endometriomas, typically larger than 3 cm; those with prior surgery for unilateral endometrioma who exhibit ipsilateral or contralateral recurrence; and those with unilateral endometrioma on a single ovary. However, the size criteria for endometrioma warrant further discussion. Conversely, oocyte cryopreservation is inadvisable for patients: with unilateral endometrioma smaller than 3 cm and good ovarian reserve; who have undergone surgery for bilateral endometriomas, regardless of recurrence; and who have diminished ovarian reserve. While consensus indicates that decisions regarding diminished ovarian reserve should be individualized, fertility preservation should often be considered for patients with serum anti-Müllerian hormone levels below 0.5 ng/mL. In such cases, a prolonged duration may be necessary to retrieve the desired 10 to 15 oocytes.

Keywords

References

  1. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril 2012;98:511-9. https://doi.org/10.1016/j.fertnstert.2012.06.029
  2. Giudice LC. Clinical practice: endometriosis. N Engl J Med 2010;362:2389-98. https://doi.org/10.1056/NEJMcp1000274
  3. Stilley JA, Birt JA, Sharpe-Timms KL. Cellular and molecular basis for endometriosis-associated infertility. Cell Tissue Res 2012;349:849-62. https://doi.org/10.1007/s00441-011-1309-0
  4. Warzecha D, Szymusik I, Wielgos M, Pietrzak B. The impact of endometriosis on the quality of life and the incidence of depression: a cohort study. Int J Environ Res Public Health 2020;17:3641. https://doi.org/10.3390/ijerph17103641
  5. Macer ML, Taylor HS. Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility. Obstet Gynecol Clin North Am 2012;39:535-49. https://doi.org/10.1016/j.ogc.2012.10.002
  6. Cramer DW, Missmer SA. The epidemiology of endometriosis. Ann N Y Acad Sci 2002;955:11-22. https://doi.org/10.1111/j.1749-6632.2002.tb02761.x
  7. D'Hooghe TM, Debrock S, Hill JA, Meuleman C. Endometriosis and subfertility: is the relationship resolved? Semin Reprod Med 2003;21:243-54. https://doi.org/10.1055/s-2003-41330
  8. AlKudmani B, Gat I, Buell D, Salman J, Zohni K, Librach C, et al. in vitro fertilization success rates after surgically treated endometriosis and effect of time interval between surgery and in vitro fertilization. J Minim Invasive Gynecol 2018;25:99-104. https://doi.org/10.1016/j.jmig.2017.08.641
  9. Holoch KJ, Lessey BA. Endometriosis and infertility. Clin Obstet Gynecol 2010;53:429-38. https://doi.org/10.1097/GRF.0b013e3181db7d71
  10. Harada T, Iwabe T, Terakawa N. Role of cytokines in endometriosis. Fertil Steril 2001;76:1-10. https://doi.org/10.1016/S0015-0282(01)01816-7
  11. Lebovic DI, Mueller MD, Taylor RN. Immunobiology of endometriosis. Fertil Steril 2001;75:1-10. https://doi.org/10.1016/S0015-0282(00)01630-7
  12. Mahutte NG, Arici A. New advances in the understanding of endometriosis related infertility. J Reprod Immunol 2002;55:73-83. https://doi.org/10.1016/S0165-0378(01)00130-9
  13. Gupta Su Goldberg JM, Aziz N, Goldberg E, Krajcir N, Agarwal A. Pathogenic mechanisms in endometriosis-associated infertility. Fertil Steril 2008;90:247-57. https://doi.org/10.1016/j.fertnstert.2008.02.093
  14. Bulun SE. Endometriosis. N Engl U Med 2009;360:268-79. https://doi.org/10.1056/NEJMra0804690
  15. Garrido N, Navarro J. Remohi J, Simon C. Pellicer A. Follicular hormonal environment and embryo quality in women with endometriosis. Hum Reprod Update 2000;6:67-74. https://doi.org/10.1093/humupd/6.1.67
  16. Pellicer A. Albert C Garrido N. Navarro J. Remohi J. Simon C. The pathophysiology of endometriosis-associated infertility: follicular environment and embryo quality. J Reprod Fertil Suppl 2000;55:109-19.
  17. Ohata Y. Harada T. Miyakoda H, Taniguchi F, lwabe T. Terakawa N. Serum interleukin-8 levels are elevated in patients with ovarian endometrioma. Fertil Steril 2008;90:994-9. https://doi.org/10.1016/j.fertnstert.2007.07.1355
  18. Velasco IAcien P, Campos A, Acien MI, Ruiz-Macia E. Interleukin-6 and other soluble factors in peritoneal fluid and endometriomas and their relation to pain and aromatase expression. J Reprod Immunol 2010;84:199-205. https://doi.org/10.1016/j.jri.2009.11.004
  19. Corachan A, Pellicer N, Pellicer A, Ferrero H. Novel therapeutic targets to improve IVF outcomes in endometriosis patients. a review and future prospects. Hum Reprod Update 2021;27:923-72, https://doi.org/10.1093/humupd/dmab014
  20. Muzii L. Di Tucci C. Di Feliciantonio M, Galati G, Di Donato V, Musella A, et al. Antimullerian hormone is reduced in the presence of ovarian endometriomas: a systematic revIew and me-ta-analysis. Fertil Steril 2018;110:932-40. https://doi.org/10.1016/j.fertnstert.2018.06.025
  21. Karadag C. Yoldemir T Demircan Karadag S. Turgut A. The effects of endometrioma size and bilaterality on ovarian reserve. J Obstet Gynaecol 2020;40:531-6. https://doi.org/10.1080/01443615.2019.1633518
  22. Zeng C, Lu R, Li X, Kuai Y. Wang S. Xue Q. The presence of ovarian endometrioma adversely affect ovarian reserve and response to stimulation but not oocyte quality or IVF/ICSI outcomes: a retro-spective cohort study. J Ovarian Res 2022;15:116. https://doi.org/10.1186/s13048-022-01042-9
  23. Sanchez AM, Vigano P, Somigliana E, Panina-Bordignon P, Vercelli-ni P, Candiani M. The distinguishing cellular and molecular features of the endometriotic ovarian cyst: from pathophysiology to the potential endometrioma-mediated damage to the ovary. Hum Reprod Update 2014;20:217-30. https://doi.org/10.1093/humupd/dmt053
  24. Hamdan M, Dunselman G, Li TC, Cheong Y. The impact of endo-metrioma on IVF/ICSI outcomes: a systematic review and me-ta-analysis. Hum Reprod Update 2015;21:809-25. https://doi.org/10.1093/humupd/dmv035
  25. Benaglia L. Bermejo A, Somigliana E, Faulisi S, Ragni G, Fedele L. et al. in vitro fertilization outcome in women with unoperated bilateral endometriomas, Fertil Steril 2013;99:1714-9. https://doi.org/10.1016/j.fertnstert.2013.01.110
  26. Kamath MS, Subramanian V. Antonisamy B, Sunkara SK. Endometriosis and oocyte quality: an analysis of 13614 donor oocyte recipient and autologous IVF cycles. Hum Reprod Open 2022;2022:hoac025. https://doi.org/10.1093/hropen/hoac025
  27. Hart RJ, Hickey M, Maouris P Buckett W. Excisional surgery versus ablative surgery for ovarian endometriomata. Cochrane Database Syst Rev 2008;2:CD004992. https://doi.org/10.1002/14651858.CD004992.pub3
  28. Dunselman GA, Vermeulen N, Becker C. Calhaz-Jorge C. D'Hooghe T. De Bie B, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod 2014;29:400-12. https://doi.org/10.1093/humrep/det457
  29. Younis JS, Shapso N, Fleming R. Ben-Shlomo1 Izhaki Impact of unilateral versus bilateral ovarian endometriotic cystectomy on ovarian reserve: a systematic review and meta-analysis. Hum Re-prod Update 2019;25:375-91. https://doi.org/10.1093/humupd/dmy049
  30. Raffi F. Metwally M, Amer S. The impact of excision of ovarian endometrioma on ovarian reserve: a systematic review and me-ta-analysis. J Clin Endocrinol Metab 2012;97:3146-54. https://doi.org/10.1210/jc.2012-1558
  31. Somigliana E, Berlanda N, Benaglia L. Vigano P, Vercellini P, Fedele L. Surgical excision of endometriomas and ovarian reserve: a systematic revIew on serum antimullerian hormone level modifications. Fertil Steril 2012;98:1531-8. https://doi.org/10.1016/j.fertnstert.2012.08.009
  32. Muzii L. Di Tucci C. Di Feliciantonio M, Marchetti C. Perniola G, Panici PB. The effect of surgery for endometrioma on ovarian reserve evaluated by antral follicle count: a systematic revIew and meta-analysis. Hum Reprod 2014;29:2190-8. https://doi.org/10.1093/humrep/deu199
  33. Demirol A, Guven S. Baykal C. Gurgan T. Effect of endometrioma cystectomy on IVF outcome: a prospective randomized study. Reprod Biomed Online 2006;12:639-43. https://doi.org/10.1016/S1472-6483(10)61192-3
  34. Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, et al. Fertility preservation in patients with Cancer: ASCO clinical practice guideline update. J Clin Oncol 2018;36:1994-2001. https://doi.org/10.1200/JCO.2018.78.1914
  35. Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril 2013;99:37-43. https://doi.org/10.1016/j.fertnstert.2012.09.028
  36. ESHRE Guideline Group on Female Fertility Preservation; Ander-son RA, Amant F, Braat D, D'Angelo A, Chuva de Sousa Lopes SM, et al. ESHRE guideline: female fertility preservation. Hum Reprod Open 2020;2020:hoaa052. https://doi.org/10.1093/hropen/hoaa052
  37. Becker CM, Bokor A, Heikinheimo O. Horne A, Jansen F Kiesel L, et al. ESHRE guideline: endometriosis. Hum Reprod Open 2022;2022:hoac009.
  38. Llarena NC, Falcone TiFlyckt RL. Fertility preservation in women with endometriosis. Clin Med Insights Reprod Health 2019;13:1179558119873386. https://doi.org/10.1177/1179558119873386
  39. Jee BC. Efficacy of ablation and sclerotherapy for the management of ovarian endometrioma: a narrative review. Clin Exp Re-prod Med 2022;49:76-86. https://doi.org/10.5653/cerm.2021.05183
  40. Rangi S. HurC Richards E, Falcone T. Fertility preservation in women with endometriosis. J Clin Med 2023;12:4331. https://doi.org/10.3390/jcm12134331
  41. Courbiere B, Le Roux E, Mathieu d'Argent E, Torre A, Patrat C. Poncelet C, et al. Oocyte vitrification for fertility preservation in women with benign gynecologic disease: French clinical practice guidelines developed by a modified Delphi Consensus Process. J Clin Med 2021;10:3810. https://doi.org/10.3390/jcm10173810
  42. Yu EH, Joo JK. Commentary on the new 2022 European Society of Human Reproduction and Embryology (ESHRE) endometriosis guidelines. Clin Exp Reprod Med 2022;49:219-24. https://doi.org/10.5653/cerm.2022.05603
  43. Muzii L Galati G, Di Tucci C. Di Feliciantonio M, Perniola G, Di Do-nato V, et al. Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain. Gynecol Endocrinol 2020; 36: 81-3. https://doi.org/10.1080/09513590.2019.1640199
  44. Somigliana E. Vigano P, Filippi F, Papaleo E, Benaglia L, Candiani M, et al. Fertility preservation in women with endometriosis: for all, for some, for none? Hum Reprod 2015:30:1280-6. https://doi.org/10.1093/humrep/dev078
  45. Doyle JO, Richter KS, Lim J. Stillman RJ, Graham JR, Tucker MJ. Successful elective and medically indicated oocyte vitrification and warming for autologous in vitro fertilization, with predicted birth probabilities for fertility preservation according to number of cryopreserved oocytes and age at retrieval. Fertil Steril 2016;105:459-66. https://doi.org/10.1016/j.fertnstert.2015.10.026
  46. Practice Committee of the American Society for Reproductive Medicine. Evidence-based outcomes after oocyte cryopreserva-tion for donor oocyte in vitro fertilization and planned oocyte cryopreservation: a guideline. Fertil Steril 2021;116:36-47. https://doi.org/10.1016/j.fertnstert.2021.02.024
  47. Cobo A. Giles J. Paolelli S Pellicer A, Remohi J, Garcia-Velasco JA. Oocyte vitrification for fertility preservation in women with endometriosis: an observational study. Fertil Steril 2020;113:836-44. https://doi.org/10.1016/j.fertnstert.2019.11.017
  48. Cobo A, Coello A. de Los Santos MJ, Giles J, Pellicer A. Remohi J, et al. Number needed to freeze: cumulative live birth rate after fertility preservation in women with endometriosis. Reprod Biomed Online 2021;42:725-32. https://doi.org/10.1016/j.rbmo.2020.12.013
  49. Henry L, Vervier J, Boucher A, Brichant G, Gaspard O, Labied S, et al. Oocyte cryopreservation in patients with endometriosis: current knowledge and number needed to treat. J Clin Med 2022;11:4559. https://doi.org/10.3390/jcm11154559